Floxsafe/Floxsafe IV Use In Pregnancy & Lactation

Floxsafe: Pregnancy: The safety of moxifloxacin in human pregnancy has not been evaluated. Animal studies have shown reproductive toxicity. The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, moxifloxacin must not be used in pregnant women.
Breastfeeding: There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during moxifloxacin therapy.
Fertility: Animal studies do not indicate impairment of fertility.
Floxsafe IV: The safety of moxifloxacin in pregnancy has not been established, therefore, this drug must not be used in pregnant women (Reversible joint injuries have been reported in children who take some quinolone. However, these have not been observed in fetus exposed to moxifloxacin. Animal studies have shown reproductive toxicity and the potential risk for humans is unknown).
The damage to weight-bearing cartilage of immature animals has been caused by moxifloxacin like other quinolones. Quinolones has known to be excreted in human milk. In pre-clinical studies, small amount of moxifloxacin has been excreted in human milk. Therefore, this drug is not administered to nursing mothers.